ALIMTA
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Aug 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
ALIMTA by Eli Lilly and Company is folate-dependent metabolic processes essential for cell replication. Approved for non-small cell lung cancer, non-small cell lung cancer [see clinical studies ()]. First approved in 2004.
Drug data last refreshed 51m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALIMTA (pemetrexed) is a small-molecule antifolate chemotherapy agent approved in 2004 for non-small cell lung cancer. It works by inhibiting folate-dependent enzymes (thymidylate synthase, dihydrofolate reductase, and GARFT) essential for DNA synthesis, blocking tumor cell replication. The drug is administered via intravenous injection and is converted intracellularly to active polyglutamate forms that are retained in cancer cells.
$0.002BPart D
LOE ApproachingProduct is in late stages of market lifecycle with modest Part D presence (305 claims, $2M spending in 2023), suggesting smaller commercial teams and defensive positioning strategies.
Mechanism of Action
folate-dependent metabolic processes essential for cell replication. In vitro studies show that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in the de novo biosynthesis…
Indications (1)
Clinical Trials (20)
TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer
Started Jul 2011
148 enrolled
Carcinoma, Non Small Cell Lung
A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer
Started Nov 2009
236 enrolled
Non Small Cell Lung Cancer
Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma
Started Jan 2009
6 enrolled
MesotheliomaPleural Mesothelioma
Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)
Started Jan 2009
18 enrolled
Central Nervous System Lymphoma
Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2
Started Apr 2008
228 enrolled
Non Small Cell Lung Carcinoma
Worked on ALIMTA at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.